Contineum Therapeutics (CTNM)

• Market cap: $175M
• 1 day: -2.59%
• 5 days: -0.44%
• 1 month: 81.50%
• 3 months: 76.30%
• 6 months: -12.42%
• Year to date: -53.25%
• 1 year: -60.82%
• 5 years: -56.04%
• 10 years: -56.04%
• Sector: Healthcare
• Industry: Biotechnology

About: Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Employees: 41

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 5 (+1) [Q1 2025]

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

6% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 18

0% more funds holding

Funds holding: 62 [Q4 2024] → 62 (+0) [Q1 2025]

3.86% less ownership

Funds ownership: 82.87% [Q4 2024] → 79.0% (-3.86%) [Q1 2025]

54% less capital invested

Capital invested by funds: $231M [Q4 2024] → $106M (-$126M) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20 195% upside
• Avg. target: $26 277% upside
• High target: $31 358% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Morgan Stanley Jeffrey Hung	195% upside $20	Overweight Maintained	19 May 2025
RBC Capital Brian Abrahams	358% upside $31	Outperform Reiterated	15 May 2025